Literature DB >> 8589283

Atypical hyperlipidemia and nephropathy associated with apolipoprotein E homozygosity.

D Ellis1, T J Orchard, S Lombardozzi, E J Yunis, J McCauley, R Agostini, J R Diamond.   

Abstract

Hyperlipidemia has been implicated in the pathogenesis of experimental progressive glomerulosclerosis, but its role in human renal injury is controversial. This report describes a 12-yr-old boy presenting with massive proteinuria, hepatomegaly, anemia, severe mixed hyperlipidemia, and progressive renal failure. The initial renal biopsy disclosed large numbers of foam cells that were shown to be monocytes. Evidence is presented suggesting that apoprotein-E2 homozygosity in our patient, together with an 88% reduction in plasma lipoprotein lipase activity associated with severe nephrotic syndrome, is responsible for the atypical clinical features, lipoprotein phenotype III with chylomicronemia, and renal lipidosis. A regimen of dietary lipid restriction, gemfibrozil, and niacin resulted in significant but partial improvement of the dyslipidemia and resolution of the hepatomegaly and ascites. This report stresses the importance of characterizing unique lipid disorders in patients with nephrotic syndrome in order to prescribe effective lipid-lowering strategies. Moreover, the striking resemblance of the clinical and nephrohistologic features of this patient to those occurring in experimental models of coexisting glomerular injury and hyperlipidemia led to the speculation that, in this setting, the hyperlipidemia may contribute to the development of progressive glomerulosclerosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8589283     DOI: 10.1681/ASN.V641170

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  7 in total

1.  Nephrotic syndrome associated with severe hypertriglyceridemia in a pediatric patient: Answers.

Authors:  Beatriz Corredor-Andrés; María Teresa Muñoz-Calvo; Olga Calero; Cristina Aparicio; Jesús Argente; Miguel Calero
Journal:  Pediatr Nephrol       Date:  2018-03-12       Impact factor: 3.714

Review 2.  Dyslipoproteinemia and impairment of renal function in diabetic kidney disease: an analysis of animal studies, observational studies, and clinical trials.

Authors:  Chi-Chih Hung; Jer-Chia Tsai; Hung-Tien Kuo; Jer-Ming Chang; Shang-Jyh Hwang; Hung-Chun Chen
Journal:  Rev Diabet Stud       Date:  2013-08-10

Review 3.  Lipoprotein glomerulopathy-like disease in a patient with type III hyperlipoproteinemia due to apolipoprotein E2 (Arg158 Cys)/3 heterozygosity.

Authors:  Miho Karube; Kimimasa Nakabayashi; Yasunori Fujioka; Ken Yoshihara; Akira Yamada; Akira Matsunaga; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2007-06-28       Impact factor: 2.801

4.  Potential of essential fatty acid deficiency with extremely low fat diet in lipoprotein lipase deficiency during pregnancy: A case report.

Authors:  Elaine C Tsai; Judy A Brown; Megan Y Veldee; Gregory J Anderson; Alan Chait; John D Brunzell
Journal:  BMC Pregnancy Childbirth       Date:  2004-12-20       Impact factor: 3.007

5.  Genetic analysis of intracapillary glomerular lipoprotein deposits in aging mice.

Authors:  Gerda A Noordmans; Yuan Huang; Holly Savage; Marcory C R F van Dijk; Gert Schaart; Marius A van den Bergh Weerman; Peter Heeringa; Jan-Luuk Hillebrands; Ron Korstanje; Harry van Goor
Journal:  PLoS One       Date:  2014-10-29       Impact factor: 3.240

6.  Severe Hypertriglyceridemia due to a novel p.Q240H mutation in the Lipoprotein Lipase gene.

Authors:  Angela Ganan Soto; Adam McIntyre; Sungeeta Agrawal; Shara R Bialo; Robert A Hegele; Charlotte M Boney
Journal:  Lipids Health Dis       Date:  2015-09-04       Impact factor: 3.876

7.  Glomerulopathy with homozygous apolipoprotein e2: a report of three cases and review of the literature.

Authors:  Kunio Kawanishi; Anri Sawada; Ayami Ochi; Takahito Moriyama; Michihiro Mitobe; Toshio Mochizuki; Kazuho Honda; Hideaki Oda; Toshio Nishikawa; Kosaku Nitta
Journal:  Case Rep Nephrol Urol       Date:  2013-11-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.